• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Eric P. Winer, MD


  • Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP.Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance).J Clin Oncol. 2014 Aug 4.
  • Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.J Clin Oncol. 2014 Jul 10(20):2142-50.
  • Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, L├íng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, .Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer.N Engl J Med. 2014 Jun 1.
  • Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O'Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF.Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500.J Clin Oncol. 2014 Jun 2.
  • Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ.Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.J Clin Oncol. 2014 May 27.
  • Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP.Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2014 May 5.
  • Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL.Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy.Breast Cancer Res Treat. 2014 Jun(2):491-501.
  • Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU.Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2014 May 5.
  • Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.Stand up to cancer phase ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.J Clin Oncol. 2014 Apr 20;32(12):1202-9.
  • Tolaney SM, Jeong J, Guo H, Brock J, Morganstern D, Come SE, Golshan M, Bellon J, Winer EP, Krop IE.A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.Cancer Med. 2014 Apr;3(2):293-9.
  • Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA.Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study.J Clin Oncol. 2014 Mar 20;32(9):927-34.
  • Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT.Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.Cancer. 2013 Nov 15;119(22):3943-51.
  • Carey LA, Winer EP.Defining success in neoadjuvant breast cancer trials.Lancet. 2014 Feb 13.
  • Mandelblatt JS, Makgoeng SB, Luta G, Hurria A, Kimmick G, Isaacs C, Tallarico M, Barry WT, Pitcher B, Winer EP, Hudis C, Cohen HJ, Muss HB.A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901.Journal Of Geriatric Oncology. 2013 Oct;4(4):353-61.
  • Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ.Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.J Natl Compr Canc Netw. 2014 Jan;12(1):71-80.
  • Krop I, Winer EP.Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.Clin Cancer Res. 2014 Jan 1;20(1):15-20.
  • Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH.Breast cancer presentation and diagnostic delays in young women.Cancer. 2014 Jan 1;120(1):20-5.
  • Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP.A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.Breast Cancer Res Treat. 2013 Nov;142(2):405-14.
  • Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU.Prospective clinical experience with research biopsies in breast cancer patients.Breast Cancer Res Treat. 2013 Nov;142(1):203-9.
  • Ruddy KJ, Desantis SD, Gelman RS, Wu AH, Punglia RS, Mayer EL, Tolaney SM, Winer EP, Partridge AH, Burstein HJ.Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice.Breast Cancer Res Treat. 2013 Oct;141(3):421-7.
  • Metzger-Filho O, Winer EP, Krop I.Pertuzumab: optimizing HER2 blockade.Clin Cancer Res. 2013 Oct 15;19(20):5552-6.
  • Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M.Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.Breast Cancer Res Treat. 2013 Sep;141(2):255-9.
  • Rosenberg SM, Tracy MS, Meyer ME, Sepucha K, Gelber S, Hirshfield-Bartek J, Troyan S, Morrow M, Schapira L, Come SE, Winer EP, Partridge AH.Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey.Ann Intern Med. 2013 Sep 17;159(6):373-81.
  • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Eur J Cancer. 2013 Sep;49(14):2972-8.
  • Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN.A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.Breast Cancer Res Treat. 2013 Jul;140(2):331-9.
  • Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD.Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.J Clin Oncol. 2013 Jul 20;31(21):2692-8.
  • Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU.Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.Clin Breast Cancer. 2013 Aug;13(4):254-63.
  • Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC.Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.J Clin Oncol. 2013 Jul 1;31(19):2382-7.
  • Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB, .Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907.Breast Cancer Res Treat. 2013 Jun;139(2):607-16.
  • Freedman RA, He Y, Winer EP, Keating NL.Racial/Ethnic Differences in Receipt of Timely Adjuvant Therapy for Older Women with Breast Cancer: Are Delays Influenced by the Hospitals Where Patients Obtain Surgical Care?.Health Serv Res. 2013 May 13.
  • Bunnell CA, Gross AH, Weingart SN, Kalfin MJ, Partridge A, Lane S, Burstein HJ, Fine B, Hilton NA, Sullivan C, Hagemeister EE, Kelly AE, Colicchio L, Szabatura AH, Winer EP, Salisbury M, Mann S.High performance teamwork training and systems redesign in outpatient oncology.BMJ Qual Saf. 2013 May;22(5):405-13.
  • Lin NU, Thomssen C, Cardoso F, Cameron D, Cufer T, Fallowfield L, Francis PA, Kyriakides S, Pagani O, Senkus E, Costa A, Winer EP, .International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer.Breast. 2013 Apr 16.
  • Ruddy KJ, Meyer ME, Giobbie-Hurder A, Emmons KM, Weeks JC, Winer EP, Partridge AH.Long-Term Risk Perceptions of Women With Ductal Carcinoma In Situ.Oncologist. 2013 Apr 8.
  • Ruddy KJ, Giobbie-Hurder A, Giordano SH, Goldfarb S, Kereakoglow S, Winer EP, Partridge AH.Quality of life and symptoms in male breast cancer survivors.Breast. 2013 Apr;22(2):197-9.
  • Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU.Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era.Breast. 2013 Jan 23.
  • Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, Baldwin RM, Owzar K, Jiang C, Watson D, Shterev I, Kubo M, Zembutsu H, Winer EP, Hudis CA, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL, , Cox NJ, Dolan ME.Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.Clin Cancer Res. 2013 Jan 15;19(2):491-9.
  • Partridge AH, Ruddy KJ, Kennedy J, Winer EP.Model program to improve care for a unique cancer population: young women with breast cancer.J Oncol Pract. 2012 Sep;8(5):e105-10.
  • Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C.Six cycles of Doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: cancer and leukemia group B 40101.J Clin Oncol. 2012 Nov 20;30(33):4071-6.
  • Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T.Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.Breast Cancer Res Treat. 2012 Nov 11.
  • Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH.Body image in recently diagnosed young women with early breast cancer.Psycho Oncology. 2012 Nov 7.
  • Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC.Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.Cancer. 2012 Nov 15;118(22):5463-72.
  • Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH.Time to diagnosis and breast cancer stage by race/ethnicity.Breast Cancer Res Treat. 2012 Oct 26.
  • Mayer EL, Isakoff SJ, Klement G, Downing SR, Chen WY, Hannagan K, Gelman R, Winer EP, Burstein HJ.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast Cancer Res Treat. 2012 Nov;136(1):169-78.
  • Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, Watson D, Eclov RJ, Mefford J, McLeod HL, Friedman PN, Hudis CA, Winer EP, Jorgenson EM, Witte JS, Shulman LN, Nakamura Y, Ratain MJ, Kroetz DL.A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.Clin Cancer Res. 2012 Sep 15;18(18):5099-109.
  • Hudis CA, Citron ML, Muss H, Norton L, Winer EP.Can we really use retrospective subset analyses and surveillance, epidemiology, and end results data to drive clinical practice?.J Clin Oncol. 2012 Sep 1;30(25):3148-9; author reply 3149-50.
  • Brooks JM, Chrischilles EA, Landrum MB, Wright KB, Fang G, Winer EP, Keating NL.Survival implications associated with variation in mastectomy rates for early-staged breast cancer.Int J Surg Oncol. 2012;2012:127854.
  • Ligibel JA, Winer EP.Aromatase inhibition in obese women: how much is enough?.J Clin Oncol. 2012 Aug 20;30(24):2940-2.
  • Ligibel JA, O'Malley AJ, Fisher M, Daniel GW, Winer EP, Keating NL.Patterns of bone density evaluation in a community population treated with aromatase inhibitors.Breast Cancer Res Treat. 2012 Aug;134(3):1305-13.
  • Keating NL, Kouri EM, He Y, West DW, Winer EP.Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis.Cancer. 2012 Jul 25.
  • Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP.TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.J Clin Oncol. 2012 Jul 20;30(21):2615-23.
  • Bober SL, Giobbie-Hurder A, Emmons KM, Winer E, Partridge A.Psychosexual Functioning and Body Image Following a Diagnosis of Ductal Carcinoma In Situ.The Journal Of Sexual Medicine. 2012 Jul 19.
  • Partridge AH, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Tamimi RM.The effect of age on delay in diagnosis and stage of breast cancer.Oncologist. 2012;17(6):775-82.
  • Burstein HJ, Piccart-Gebhart MJ, Perez EA, Hortobagyi GN, Wolmark N, Albain KS, Norton L, Winer EP, Hudis CA.Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?.J Clin Oncol. 2012 Jun 20;30(18):2179-82.
  • Krop IE, Lorusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2 -Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine.J Clin Oncol. 2012 May 29.
  • Toi M, Winer EP, Inamoto T, Benson JR, Forbes JF, Mitsumori M, Robertson JF, Sasano H, von Minckwitz G, Yamauchi A, Klimberg VS.Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference.Ann Surg Oncol. 2011 Mar 23.
  • Morris PG, Chen C, Steingart RM, Fleisher M, Lin NU, Moy B, Come S, Sugarman S, Abbruzzi A, Lehman R, Patil S, Dickler MN, McArthur HL, Winer EP, Norton L, Hudis C, Dang CT.Troponin I and C-Reactive Protein are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib.Clin Cancer Res. 2011 Mar 3.
  • Lin NU, Winer EP.Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight.J Clin Oncol. 2011 Jan 20;29(3):251-3.
  • Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL.The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.Cancer. 2011 Jan 1;117(1):180-9.
  • Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Somlo G, Topham NS, Ward JH, Winer EP, Wolff AC.Breast cancer: noninvasive and special situations.J Natl Compr Canc Netw. 2010 Nov;8(10):1182-207.
  • Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA.Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer.Clin Cancer Res. 2010 Oct 1;16(19):4702-10.
  • Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, Winer E, Garber J.Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial.Menopause.;17(5):908-16.
  • Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A.Cardiac toxicity from systemic cancer therapy: a comprehensive review.Prog Cardiovasc Dis.;53(2):94-104. Review.
  • Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, .American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.J Clin Oncol. 2010 Aug 10;28(23):3784-96. Review.
  • Ligibel JA, Partridge A, Giobbie-Hurder A, Campbell N, Shockro L, Salinadri T, Winer EP.Physical and psychological outcomes among women in a telephone-based exercise intervention during adjuvant therapy for early stage breast cancer.J Womens Health (Larchmt). 2010 Aug;19(8):1553-9.
  • Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Paskett EM, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N, .Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.Journal of the National Cancer Institute. 2010 Jul 7;102(13):942-9.
  • Kouri EM, He Y, Winer EP, Keating NL.Influence of birthplace on breast cancer diagnosis and treatment for Hispanic women.Breast Cancer Res Treat. 2010 Jun;121(3):743-51.
  • Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H.Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.J Clin Oncol. 2010 May 10;28(14):2418-22.
  • Freedman RA, Winer EP.Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer.Breast. 2010 Apr;19(2):69-75. Review.
  • Keating NL, Landrum MB, Brooks JM, Chrischilles EA, Winer EP, Wright K, Volya R.Outcomes following local therapy for early-stage breast cancer in non-trial populations.Breast Cancer Res Treat. 2010 Apr 8.
  • Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F, .International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?.Journal of the National Cancer Institute. 2010 Apr 7;102(7):456-63. Review.
  • Ligibel JA,Giobbie-Hurder A,Olenczuk D,Campbell N,Salinardi T,Winer EP,Mantzoros CS.Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors.Cancer Causes Control. 2009 Oct;20(8):1523-8.
  • de Moor JS, Partridge AH, Winer EP, Ligibel J, Emmons KM.The role of socioeconomic status in adjustment after ductal carcinoma in situ.Cancer. 2010 Mar 1;116(5):1218-25.
  • Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.J Clin Oncol. 2010 Mar 1;28(7):1145-53.
  • Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF, .Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.Lancet Oncol. 2010 Jan;11(1):55-65.
  • Partridge AH, Winer EP.On mammography--more agreement than disagreement.N Engl J Med. 2009 Dec 24;361(26):2499-501.
  • Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT.Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.J Clin Oncol. 2009 Dec 20;27(36):6117-23.
  • Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B.Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2009 Dec 10;27(35):6052-69. Review.
  • Burstein HJ, Winer EP.Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.J Clin Oncol. 2009 Dec 1;27(34):5671-3.
  • Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E, .Protocol for the examination of specimens from patients with invasive carcinoma of the breast.Arch Pathol Lab Med. 2009 Oct;133(10):1515-38.
  • Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS, .International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.Journal of the National Cancer Institute. 2009 Sep 2;101(17):1174-81. Review.
  • Harris LN,Broadwater G,Abu-Khalaf M,Cowan D,Thor AD,Budman D,Cirrincione CT,Berry DA,Winer EP,Hudis CA,Hayes DF,Friedman P,Ellis M,Dressler L.Topoisomerase II{alpha} Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy in HER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013.J Clin Oncol. 2009 Jul 20;27(21):3430-6.
  • Keating NL, Kouri E, He Y, Weeks JC, Winer EP.Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?.Med Care. 2009 Jul;47(7):765-73.
  • Muss HB,Berry DA,Cirrincione CT,Theodoulou M,Mauer AM,Kornblith AB,Partridge AH,Dressler LG,Cohen HJ,Becker HP,Kartcheske PA,Wheeler JD,Perez EA,Wolff AC,Gralow JR,Burstein HJ,Mahmood AA,Magrinat G,Parker BA,Hart RD,Grenier D,Norton L,Hudis CA,Winer EP.Adjuvant chemotherapy in older women with early-stage breast cancer.N Engl J Med. 2009 May 14;360(20):2055-65.
  • Campos SM,Guastalla JP,Subar M,Abreu P,Winer EP,Cameron DA.A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.Clin Breast Cancer. 2009 Feb;9(1):39-44.
  • Lin NU,Dieras V,Paul D,Lossignol D,Christodoulou C,Stemmler HJ,Roche H,Liu MC,Greil R,Ciruelos E,Loibl S,Gori S,Wardley A,Yardley D,Brufsky A,Blum JL,Rubin SD,Dharan B,Steplewski K,Zembryki D,Oliva C,Roychowdhury D,Paoletti P,Winer EP.Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.Clin Cancer Res. 2009 Feb 15;15(4):1452-9.
  • Carlson RW,Allred DC,Anderson BO,Burstein HJ,Carter WB,Edge SB,Erban JK,Farrar WB,Goldstein LJ,Gradishar WJ,Hayes DF,Hudis CA,Jahanzeb M,Kiel K,Ljung BM,Marcom PK,Mayer IA,McCormick B,Nabell LM,Pierce LJ,Reed EC,Smith ML,Somlo G,Theriault RL,Topham NS,Ward JH,Winer EP,Wolff AC.Breast cancer. Clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. Review.
  • Partridge AH,Winer EP.Sharing study results with trial participants: time for action.J Clin Oncol. 2009 Feb 20;27(6):838-9.
  • Krop IE, Winer EP.Ten years of HER2-directed therapy: still questions after all these years.Breast Cancer Res Treat. 2009 Jan;113(2):207-9.
  • Winer E,Gralow J,Diller L,Karlan B,Loehrer P,Pierce L,Demetri G,Ganz P,Kramer B,Kris M,Markman M,Mayer R,Pfister D,Raghavan D,Ramsey S,Reaman G,Sandler H,Sawaya R,Schuchter L,Sweetenham J,Vahdat L,Schilsky RL.Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2009 Feb 10;27(5):812-26.
  • Freedman RA,He Y,Winer EP,Keating NL.Trends in racial and age disparities in definitive local therapy of early-stage breast cancer.J Clin Oncol. 2009 Feb 10;27(5):713-9.
  • Schneider BP,Winer EP,Foulkes WD,Garber J,Perou CM,Richardson A,Sledge GW,Carey LA.Triple-negative breast cancer: risk factors to potential targets.Clin Cancer Res. 2008 Dec 15;14(24):8010-8. Review.
  • Burstein HJ,Chen YH,Parker LM,Savoie J,Younger J,Kuter I,Ryan PD,Garber JE,Chen H,Campos SM,Shulman LN,Harris LN,Gelman R,Winer EP.VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.Clin Cancer Res. 2008 Dec 1;14(23):7871-7.
  • Freedman RA,Winer EP.Reducing disparities in breast cancer care: a daunting but essential responsibility.Journal of the National Cancer Institute. 2008 Dec 3;100(23):1661-3.
  • Wong JS, Taghian AG, Bellon JR, Keshaviah A, Smith BL, Winer EP, Silver B, Harris JR.Tangential Radiotherapy Without Axillary Surgery in Early-Stage Breast Cancer: Results of a Prospective Trial.Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):866-70.
  • Paskett ED, Herndon JE 2nd, Day JM, Stark NN, Winer EP, Grubbs SS, Pavy MD, Shapiro CL, List MA, Hensley ML, Naughton MA, Kornblith AB, Habin KR, Fleming GF, Bittoni MA.Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.Psychooncology. 2008 Nov;17(11):1108-20.
  • Ligibel JA,Partridge A,Giobbie-Hurder A,Golshan M,Emmons K,Winer EP.Physical activity behaviors in women with newly diagnosed ductal carcinoma-in-situ.Ann Surg Oncol. 2009 Jan;16(1):106-12.
  • Lin NU,Claus E,Sohl J,Razzak AR,Arnaout A,Winer EP.Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases.Cancer. 2008 Nov 15;113(10):2638-45.
  • Tolaney SM,Najita J,Winer EP,Burstein HJ.Lymphopenia associated with adjuvant anthracycline/ taxane regimens.Clin Breast Cancer. 2008 Aug;8(4):352-6.
  • Partridge A,Winer JP,Golshan M,Bellon JR,Blood E,Dees EC,Sampson E,Emmons KM,Winer E.Perceptions and management approaches of physicians who care for women with ductal carcinoma in situ.Clin Breast Cancer. 2008 Jun;8(3):275-80.
  • Bafford AC,Burstein HJ,Barkley CR,Smith BL,Lipsitz S,Iglehart JD,Winer EP,Golshan M.Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival.Breast Cancer Res Treat. 2009 May;115(1):7-12. Review.
  • Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP.The impact of sharing results of a randomized breast cancer clinical trial with study participants.Breast Cancer Res Treat. 2009 May;115(1):123-9.
  • Polite BN,Cirrincione C,Fleming GF,Berry DA,Seidman A,Muss H,Norton L,Shapiro C,Bakri K,Marcom K,Lake D,Schwartz JH,Hudis C,Winer EP.Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.J Clin Oncol. 2008 Jun 1;26(16):2659-65.
  • Dickler MN,Cobleigh MA,Miller KD,Klein PM,Winer EP.Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.Breast Cancer Res Treat. 2009 May;115(1):115-21.
  • Punglia RS, Burstein HJ, Winer EP, Weeks JC.Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.Journal of the National Cancer Institute. 2008 May 7;100(9):642-8.
  • Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP.Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2008 Apr 20;26(12):1993-9.
  • Stokes ME, Thompson D, Montoya EL, Weinstein MC, Winer EP, Earle CC.Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.Value Health. 2008 Mar-Apr;11(2):213-20.
  • Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C.Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.J Clin Oncol. 2008 Apr 1;26(10):1642-9.
  • Lin NU, Winer EP.Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.J Clin Oncol. 2008 Apr 20;26(12):1919-21.
  • Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, Chen H, Adloff K, Keshaviah A, Winer EP.Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.J Clin Oncol. 2008 Feb 20;26(6):907-12.
  • Partridge A, Adloff K, Blood E, Dees EC, Kaelin C, Golshan M, Ligibel J, de Moor JS, Weeks J, Emmons K, Winer E.Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.Journal of the National Cancer Institute. 2008 Feb 20;100(4):243-51.
  • Gralow JR, Zujewski JA, Winer E.Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.J Clin Oncol. 2008 Feb 10;26(5):696-7. Review.
  • Lin NU, Winer EP.Advances in adjuvant endocrine therapy for postmenopausal women.J Clin Oncol. 2008 Feb 10;26(5):798-805. Review.
  • Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP.Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.J Clin Oncol. 2008 Feb 10;26(5):814-9. Review.
  • Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN, Winer EP, Gelmon KA, Gersh BJ, Jaffe AS, Rodeheffer RJ.Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.J Clin Oncol. 2008 Mar 10;26(8):1231-8.
  • Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA.Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.Cancer Treat Rev. 2008 May;34(3):223-230.
  • Razzak AR, Lin NU, Winer EP.Heterogeneity of breast cancer and implications of adjuvant chemotherapy.Breast Cancer. 2008;15(1):31-4.
  • Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A.Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.J Clin Oncol. 2008 Feb 1;26(4):556-62.
  • Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W Jr, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS.Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.J Clin Oncol. 2008 Jan 10;26(2):313-25.
  • Buzdar AU, Coombes RC, Goss PE, Winer EP.Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.Cancer. 2008 Feb 1;112(3 Suppl):700-9.
  • Come SE, Buzdar AU, Ingle JN, Johnston SR, Brodie AM, Coombes RC, Miller WR, Pritchard KI, Winer EP, Zujewski JA, Goss PE.Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.Cancer. 2008 Feb 1;112(3 Suppl):673-8.
  • Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ.Care in the months before death and hospice enrollment among older women with advanced breast cancer.J Gen Intern Med. 2008 Jan;23(1):11-8.
  • Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M.Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy?.J Surg Oncol. 2007 Nov 1;96(6):474-80.
  • Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E.Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.Psychooncology. 2007 May 24;16(10).
  • Burstein HJ, Winer EP.Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors.J Clin Oncol. 2007 Sep 1;25(25):3797-9.
  • Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E.Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI.Eur J Cancer. 2007 Jul;43(11):1646-53.
  • Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.Cancer. 2007 Sep 1;110(5):965-72.
  • Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN.Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.Invest New Drugs. 2007 Aug;25(4):369-75.
  • Lin NU, Winer EP.Optimal use of aromatase inhibitors: to lead or to follow?.J Clin Oncol. 2007 Jul 1;25(19):2639-41.
  • Punglia RS, Morrow M, Winer EP, Harris JR.Local therapy and survival in breast cancer.N Engl J Med. 2007 Jun 7;356(23):2399-405. Review.
  • Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Ljung BM, Kiel K, Marks LB, McCormick B, Nabell LM, Pierce LJ, Reed EC, Silver SM, Smith ML, Somlo G, Theriault RL, Ward JH, Winer EP, Wolff AC.Invasive breast cancer.J Natl Compr Canc Netw. 2007 Mar;5(3):246-312. Review.
  • Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ.Surveillance testing among survivors of early-stage breast cancer.J Clin Oncol. 2007 Mar 20;25(9):1074-81.
  • Lin NU, Winer EP.Brain metastases: the HER2 paradigm.Clin Cancer Res. 2007 Mar 15;13(6):1648-55. Review.
  • Bullitt E, Lin NU, Ewend MG, Zeng D, Winer EP, Carey LA, Smith JK.Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer.Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv. 2006;9(Pt 2):561-8.
  • Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.Clin Cancer Res. 2007 Feb 15;13(4):1198-207.
  • Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E.Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.Psychooncology. 2007 Oct;16(10):895-903.
  • Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L.Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.Breast Cancer Res. 2006;8(6):R66.
  • Tolaney SM, Partridge AH, Sheib RG, Burstein HJ, Winer EP.Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer.J Clin Oncol. 2006 Nov 20;24(33):5330-1.
  • Leining MG, Gelber S, Rosenberg R, Przypyszny M, Winer EP, Partridge AH.Menopausal-type symptoms in young breast cancer survivors.Ann Oncol. 2006 Dec;17(12):1777-82.
  • Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP.Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.Invest New Drugs. 2007 Apr;25(2):161-4.
  • Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G.Understanding the decisions of cancer clinical trial participants to enter research studies: Factors associated with informed consent, patient satisfaction, and decisional regret.Patient Educ Couns. 2006 Oct;63(1-2):104-9.
  • Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM,.HER2 testing in breast cancer: NCCN Task Force report and recommendations.J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.
  • Burstein HJ, Mayer E, Patridge AH, O'Kane H, Litsas G, Come SE, Hudis CA, Goldstein DF, Muss HB, Winter EP, Garber JE.Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons.Clin Breast Cancer. 2006 Jun;7(2):158-61.
  • Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H,.Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.Breast Cancer Res Treat. 2006 Dec;100(3):301-8.
  • Hudis CA, Winer EP.Cancer and leukemia group B breast committee: decades of progress and plans for the future.Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3576s-80s. Review.
  • Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.Cancer. 2006 Jun 15;106(12):2576-82.
  • Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP.Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA. 2006 Apr 12;295(14):1658-67.
  • Carlson RW, Brown E, Burstein HJ, Gradishar WJ, Hudis CA, Loprinzi C, Mamounas EP, Perez EA, Pritchard K, Ravdin P, Recht A, Somlo G, Theriault RL, Winer EP, Wolff AC,.NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.J Natl Compr Canc Netw. 2006 Mar;4 Suppl 1:S1-26. Review.
  • Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C.Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):997s-1000s.
  • Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN.Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):496-504.
  • Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ.Factors related to underuse of surveillance mammography among breast cancer survivors.J Clin Oncol. 2006 Jan 1;24(1):85-94.
  • Lin NU, Gelman R, Winer EP.Dose density in breast cancer: a simple message?.J Natl Cancer Inst. 2005 Dec 7;97(23):1712-4.
  • Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS.Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy.J Clin Oncol. 2005 Nov 20;23(33):8453-60.
  • Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP.Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.J Clin Oncol. 2005 Nov 20;23(33):8340-7.
  • Peppercorn J, Partridge A, Burstein HJ, Winer EP.Standards for follow-up care of patents with breast cancer.Breast. 2005 Dec;14(6):500-8.
  • Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P.Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.Ann Oncol. 2005 Nov;16(11):1772-7.
  • Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ.Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.J Clin Oncol. 2005 Aug 1;23(22):5178-87.
  • Burstein HJ, Winer EP.HER2 or Not HER2: That Is the Question.J Clin Oncol. 2005 Jun 1;23(16):3656-9.
  • Partridge AH, Winer EP.Fertility after breast cancer: questions abound.J Clin Oncol. 2005 Jul 1;23(19):4259-61.
  • Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP.Offering participants results of a clinical trial: sharing results of a negative study.Lancet. 2005 Mar 12-18;365(9463):963-4.
  • Winer EP.Optimizing endocrine therapy for breast cancer.J Clin Oncol. 2005 Mar 10;23(8):1609-10.
  • Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA.The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.Semin Oncol. 2004 Dec;31(6 Suppl 13):106-46.
  • Partridge AH, Winer EP.Long-term complications of adjuvant chemotherapy for early stage breast cancer.Breast Dis. 2004;21:55-64.
  • Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.J Clin Oncol. 2005 Jan 20;23(3):619-29.
  • Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L.Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.J Clin Oncol. 2004 Jun 1;22(11):2061-8.
  • Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC.HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.J Clin Oncol. 2004 Mar 1;22(5):854-63.
  • Keating NL, Landrum MB, Ayanian JZ, Winer EP, Guadagnoli E.Consultation with a medical oncologist before surgery and type of surgery among elderly women with early-stage breast cancer.J Clin Oncol. 2003 Dec 15;21(24):4532-9.
  • Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.J Clin Oncol. 2003 Aug 1;21(15):2889-95.
  • Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP.Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.Breast Cancer Res Treat. 2003 Jun;79(3):391-7.
  • Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E.Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer. 2003 Jun 15;97(12):2972-7.
  • Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.J Clin Oncol. 2003 Jul 1;21(13):2597-9.
  • Earle CC, Burstein HJ, Winer EP, Weeks JC.Quality of non-breast cancer health maintenance among elderly breast cancer survivors.J Clin Oncol. 2003 Apr 15;21(8):1447-51.
  • Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L.Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia.J Clin Oncol. 2003 Apr 15;21(8):1431-9.
  • Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP.Do patients participating in clinical trials want to know study results?.J Natl Cancer Inst. 2003 Mar 19;95(6):491-2.
  • Partridge AH, Wang PS, Winer EP, Avorn J.Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.J Clin Oncol. 2003 Feb 15;21(4):602-6.
  • Ligibel JA, Winer EP.Clinical differences among the aromatase inhibitors.Clin Cancer Res. 2003 Jan;9(1 Pt 2):473S-9S.
  • Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP.Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.J Clin Oncol. 2003 Jan 1;21(1):46-53.
  • Skinner CS, Schildkraut JM, Berry D, Calingaert B, Marcom PK, Sugarman J, Winer EP, Iglehart JD, Futreal PA, Rimer BK.Pre-counseling education materials for BRCA testing: does tailoring make a difference?.Genet Test. 2002 Summer;6(2):93-105.
  • Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.J Clin Oncol. 2002 Aug 1;20(15):3317-27.
  • Partridge AH, Winer EP.Informing clinical trial participants about study results.JAMA. 2002 Jul 17;288(3):363-5.
  • Partridge AH, Burstein HJ, Winer EP.Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer.J Natl Cancer Inst Monogr. 2001(30):135-42.
  • Winer EP, Burstein HJ.New combinations with Herceptin in metastatic breast cancer.Oncology. 2001;61 Suppl 2:50-7.
  • Bluman LG, Borstelmann NA, Rimer BK, Iglehart JD, Winer EP.Knowledge, satisfaction, and perceived cancer risk among women diagnosed with ductal carcinoma in situ.J Womens Health Gend Based Med. 2001 Jul-Aug;10(6):589-98.
  • Sparano JA, Winer EP.Liposomal anthracyclines for breast cancer.Semin Oncol. 2001 Aug;28(4 Suppl 12):32-40.
  • Partridge AH, Bunnell CA, Winer EP.Quality of life issues among women undergoing high-dose chemotherapy for breast cancer.Harrison's Principles of Internal Medicine. 2001 Winter;14:41-50.
  • Burstein HJ, Bunnell CA, Winer EP.New cytotoxic agents and schedules for advanced breast cancer.Semin Oncol. 2001 Aug;28(4):344-58.
  • Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.J Clin Oncol. 2001 May 15;19(10):2722-30.
  • Warren Burhenne LJ, Wood SA, D'Orsi CJ, Feig SA, Kopans DB, O'Shaughnessy KF, Sickles EA, Tabar L, Vyborny CJ, Castellino RA.Potential contribution of computer-aided detection to the sensitivity of screening mammography.Radiology. 2000 May;215(2):554-62.
  • Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP.Docetaxel administered on a weekly basis for metastatic breast cancer.J Clin Oncol. 2000 Mar;18(6):1212-9.
  • Goss PE, Winer EP, Tannock IF, Schwartz LH.Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.J Clin Oncol. 1999 Jan;17(1):52-63.
  • Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA.Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Med Decis Making. 1998 Oct-Dec;18(4):365-75.
  • Winer EP, Lindley C, Hardee M, Sawyer WT, Brunatti C, Borstelmann NA, Peters W.Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.Psychooncology. 1999 Mar-Apr;8(2):167-76.
  • Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR.Is axillary lymph node dissection indicated for early-stage breast cancer? A decision analysis.J Clin Oncol. 1999 May;17(5):1465-73.
  • Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP.Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2.J Clin Oncol. 1999 Mar;17(3):1040-6.
  • Havlin KA, Ramirez MJ, Legler CM, Harris LN, Matulonis UA, Hohneker JA, Hayes DF, Winer EP.Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.Cancer Chemother Pharmacol. 1999;43(1):68-72.
  • Bunnell CA, Winer EP.Oral 5-FU analogues in the treatment of breast cancer.Oncology (Huntingt). 1998 Oct;12(10 Suppl 7):39-43.
  • Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, Winer EP.Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey.Cancer. 1998 Oct 1;83(7):1362-8.
  • Iglehart JD, Miron A, Rimer BK, Winer EP, Berry D, Shildkraut MJ.Overestimation of hereditary breast cancer risk.Ann Surg. 1998 Sep;228(3):375-84.
  • Thomason TE, McCune JS, Bernard SA, Winer EP, Tremont S, Lindley CM.Cancer pain survey: patient-centered issues in control.J Pain Symptom Manage. 1998 May;15(5):275-84.
  • Lindley C, Vasa S, Sawyer WT, Winer EP.Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer.J Clin Oncol. 1998 Apr;16(4):1380-7.
  • Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, Winer EP.Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.Am J Clin Nutr. 1997 May;65(5):1495-501.
  • Demark-Wahnefried W, Rimer BK, Winer EP.Weight gain in women diagnosed with breast cancer.J Am Diet Assoc. 1997 May;97(5):519-26, 529; quiz 527-8.
  • Warmuth MA, Sutton LM, Winer EP.A review of hereditary breast cancer: from screening to risk factor modification.Am J Med. 1997 Apr;102(4):407-15.
  • Sutton LM, Warmuth MA, Petros WP, Winer EP.Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.Cancer Chemother Pharmacol. 1997;40(4):335-41.